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74.6±0.3	 74.0±0.3	 23.6±0.3	 23.2±0.3	 <.0005	 	
Height		
(m)	
1.74±0.01	 1.61±0.01	 1.81±0.01	 1.67±0.01	 <.0005	 <.0005	
Body	mass	
(kg)	
78.8±1.0	 65.1±0.8	 75.4±1.2	 62.4±1.0	 <.0005	 .018	
BMI	
(kg/m2)	
25.8±0.3	 25.2±0.3	 23.1±0.3	 22.4±0.3	 .017	 <.0005	
Body	fat	
(kg)	
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1	 2	 1	 2	 1	 2	
DKK1	 r=.107	
p=.026	
r=.129	
p=.008	
r=.167	
p=.007	
r=.174	
p=.005	
r=.263	
p=.001	
r=.282	
p<.0005	
FGF-23	 r=.067	
p=.274	
r=.051	
p=.406	
r=-.095	
p=.235	
r=-.079	
p=.330	
r=-.086	
p=.370	
r=-.130	
p=.182	
OC	 r=-.124	
p=.010	
r=-.083	
p=.088	
r=.150	
p=.015	
r=.187	
p=.003	
r=-.023	
p=.767	
r=-.008	
p=.916	
OPG	 r=-.096	
p=.047	
r=-.039	
p=.419	
r=.209	
p=.001	
r=.254	
p<.0005	
r=.081	
p=.297	
r=.055	
p=.484	
OPN	 r=-.005	
p=.918	
r=-.001	
p=.980	
r=.055	
p=.370	
r=.073	
p=.245	
r=-.120	
p=.124	
r=-.122	
p=.120	
Sclerostin	 r=-.091	
p=.059	
r=-.075	
p=.126	
r=.241	
p<.0005	
r=.240	
p<.0005	
r=.129	
p=.096	
r=.135	
p=.086	
	2	
Data	are	shown	as	spearman’s	rho.	The	circulating	bone	regulatory	factors	were	log-transformed	and	their	z-3	
scores	calculated.	The	p	value	indicates	the	level	of	significance	after	statistical	analysis.	Results	were	adjusted	4	
for	1)	country;	2)	country,	z-score	lean	mass,	z-score	BMI,	self-reported	health	and	supplement	use.	Significant	5	
relationships	are	highlighted	using	bold	text.	6	
	7	
	 	8	
	 15	
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